Nanotechnology for delivery of drugs and biomedical applications

Current Clinical Pharmacology

Volumn 5, Issue 4, 2010, Pages 257-280

  Leucuta, Sorin Emilian ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Biology; Drug delivery systems; Medicine; Nanoparticles; Nanotechnology; Pharmacy

Indexed keywords

DIAGNOSTIC AGENT; NANOMATERIAL; NANOPARTICLE; POLYMER;

APPARATUS, EQUIPMENT AND SUPPLIES; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METHODOLOGY; REVIEW; TISSUE ENGINEERING;

DRUG DELIVERY SYSTEMS; EQUIPMENT AND SUPPLIES; HUMANS; NANOPARTICLES; NANOSTRUCTURES; POLYMERS; TISSUE ENGINEERING;

EID: 79952278110     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410793352003     Document Type: Article

References (250)

1. Hillery AM, Lloyd AW, Swarbrick J, Eds. Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists. London: Francis &Taylor 2001.
2. Petrak K. Essential properties of drug-targeting delivery systems. Drug Discov Today (DDT) 200; 10: 1667-73.
3. Lee VHL. Advanced drug delivery in the post-genomic era. Editorial. Adv Drug Deliv Rev 2009; 61: 1389-90.
4. Jain KK. Nanomedicine: Application of nanobiotechnology in medical practice. Med Princ Pract 2008; 17: 89-101.
5. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005; 6: 3-5.
6. Pathak Y, Thassu D. Drug delivery nanoparticles. Formulation and characterization. Series: Drugs and pharmaceutical sciences, 2nd ed, Informa, 2009.
7. Jain NK. Bhooshan B Ed. Pharmaceutical nanotechnology, In: Handbook of Nanotechnology. Springer 2004.
8. Hornyak GL, Tibbals HF. Fundamentals of nanotechnology. CRC Press 2008.
9. Bhoosan B, Ed. Springer Handbook of Nanotechnology. Berlin, New York: Springer-Verlag, 2004.
10. Leucuta SE. Micro and nanoparticles as drug carriers. In: Risks NBC, Sohns T, Voicu VA, Eds. Kluwer Acad Pub 1999; 411-39.
11. Murthy SK. Nanoparticles in modern medicine: State of the art and future challenges. Int J Nanomed 2007; 2: 129-41.
12. Langer R, Peppas NA. Advances in biomaterials, drug delivery, and bionanotechnology AIChE J 2003; 49: 2990-3006.
13. Lee SC, Ruegsegger M, Barnes PD, Smith BR, Ferrari M. Therapeutic nanodevices, In: Booshan B, Ed. Handbook of Nanotechnology, Springer 2004; pp. 279-322.
14. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci 2008; 97: 3518-90.
15. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 2006; 1: 5-20.
16. Allen TM. Ligand targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-63.
17. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size dependent internalization of particles via the pathways of clathrin and caveolae mediated endocytosis. Biochem J 2004; 377: 159-169.
18. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713-22.
19. Kostarelos K. Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. Adv Colloid Interface Sci 2003; 106: 147-168.
20. Moghimi SM, Hunter AC, Murray JK. Nanomedicine: current status and future prospects. Adv Drug Deliv Rev 2005; 17: 61-73.
21. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9:E128-E147.
22. Van Vlerken LE, Amiji MM. Multi functional polymeric nanoparticles for tumor targeted drug delivery. Expert Opin Drug Deliv 2006; 3: 205-16.
23. Storm G, Belliot SO, Daemen T, Lasic D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17: 31-48.
24. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009; 26: 1025-58.
25. Labarre D, Vauthier C, Chauvierre C, Petri B, Muller R, Chehimi MM. Interactions of blood proteins with a poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 2005; 26: 5075-84.
26. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-67.
27. Bertholon I, Ponchel G, Labarre D, Couvreur P, Vauthier C. Bioadhesive properties of poly(alkylcyanoacrylate) nanoparticles coated with polysaccharide. J Nanosci Nanotechnol 2006; 6: 3102-9.
28. Porfire AS, Zabaleta V, Gamazo C, Leucuta SE, Irache JM. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles. Int J Pharm, 2010; 390: 37-44.
29. Porfire A S, Parvu A E, Daicoviciu D, Leucuta S E. Evaluation of antiinflammatory activity of liposomes encapsulated superoxide dismutase in rats peritonitis. Farmacia 2009; 57: 412-23.
30. Porfire A S, Tomuta I, Irache J M, Leucuta S E. The influence of the formulation factors on physico-chemical properties of dextran associated Gantrez-AN nanoparticles. Farmacia 2009; 57: 463-472.
31. Lee JF, Foote RS. Micro and nano technologies in bioanalysis. New York: Humana Press 2009.
32. Marcato PD, Duran N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 2008; 8: 1-14.
33. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-52.
34. Siegel DP, Tenchov BG. Influence of the lamellar phase unbinding energy on the relative stability of lamellar and inverted cubic phases. Biophys J 2008; 94: 3987-95.
35. Mozafari MR, Mortazavi SM. Nanoliposomes: From fundamentals to recent developments. Oxford, Trafford Pub.Ltd. 2005.
36. Mozafari MR, Johnson C, Hatziantoniou S, Demetzos C. Nanoliposomes and their applications in food nanotechnology. J Liposome Res 2008; 18: 309-27.
37. Gregoriadis G, Ed. Liposome Technology, 2nd ed. Boca Raton: CRC Press,1993.
38. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154: 123-40.
39. Szoka F, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann Rev Biophys Bioeng 1980; 9: 467-508.
40. Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M. New generation of liposomal drugs for cancer. Anti Cancer Agents Med Chem 2006; 6: 537-52.
41. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomed 2006; 1: 297-315.
42. Huwyler J, Drewe J, Krahenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomed 2008; 3: 21-9.
43. Kozlowska D, Foran P, MacMahon P, Shelly MJ. The value of immunoliposomes. Adv Drug Deliv Rev 2009; 61: 1402-11.
44. Gregoriadis G, Bacon A, Caparros Wanderley W, McCormack B. Plasmid DNA vaccines: entrapment into liposomes by dehydrationrehydration. Methods Enzymol 2003; 367: 70-80.
45. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother (Florence, Italy) 2004; 16 Suppl: 94-7.
46. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949-53.
47. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
48. Allen C, Dos SN, Gallagher R, et al. Controlling physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 2002; 2: 225-50.
49. Harris JM. Poly(ethylene glycol) chemistry: biotechnical and biomedical applications. New York and London: Plenum Press, 1992.
50. Gabizon AA, Muggia FM. Long circulating liposomes: old drugs, new therapeutics. Springer-Verlag, 1998.
51. Lopez De Menezes DE, Kirchmeyer MJ, et al. Cellular trafficking and cytotoxicity of anti-CD19 targeted liposomal doxorubicin in B lymphoma cells. J Liposome Res 1999; 9: 199-228.
52. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004; 10: 2981-9.
53. Muller RH, Menhert W, Lucks JS, Schwartz C, Muhlen H, Weyhers H, Freitas C, Ruhl D. Solid lipid nanoparticles (SLN) an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995; 41: 62-9.
54. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-8.
55. Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002; 10: 387-96.
56. Domb AJ, Maniar M. Lipospheres for controlled delivery of pharmaceuticals, pesticides, fertilizers. Nova Pharmaceutical Corp. 90-US6519(9107171). 1990; 79: 8-11.
57. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-72.
58. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504.
59. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery [58] Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504.
60. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59: 478-90.
61. Mehnert W, Mader K. SLN production, characterization and application. Adv Drug Deliv Rev 2001; 47: 165-96.
62. Domb AJ, Maniar M. Lipospheres for controlled delivery of pharmaceuticals, pesticides, fertilizers. Nova Pharmaceutical Corp. 90-US6519(9107171).1990; 79: 8-11.
63. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-72.
64. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504.
65. Tseng YC, Mozumdar S, Huang L. Lipid based systemic delivery of siRNA. Adv Drug Deliv Rev 2009; 61: 721-31
66. Mehnert W, Mader K. SLN production, characterization and application. Adv Drug Deliv Rev 2001; 47: 165-96.
67. Roszek B, de Jong WH, Geertsma RE. Nanotechnology in medical applications: state of the art in materials and devices. 2005; RIVM Report 265001001
68. Murray CB, Norris DJ, Bawendi MG. Synthesis and characterization of nearly monodisperse CdE (E= S,Se, Te) semiconductor nanocrystallites. J Am Chem Soc 1993; 115: 8706-15.
69. Juzenas P, Chen W, Sun YP, et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev 2008; 60: 1600-14.
70. Hezinger AFE, Tessmar J, Gopferich A. Polymer coating of quantum dots, a powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm 2008; 68: 138-52.
71. Medintz IL, Mattoussi H, Clapp AR. Potential clinical applications of quantum dots. Int J Nanomed 2008; 3: 151-67.
72. Kroto HW, Heath JR, O Brien SC, Curlk RF, Smalley RE. Buckminsterfullerene. Nature 1985; 318: 162-3.
73. Iijima S. Helical microtubules of graphitic carbon. Nature 1991; 354: 56-8.
74. Sun YP, Fu K, Lin Y, Huang W. Functionalized carbon nanotubes, properties and applications. Acc Chem Res 2002; 35: 1095-104.
75. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev 2006; 58: 1460-70.
76. Bianco A, Hoebeke J, Kostarelos K, Prato M, Partidos CD. Carbon nanotubes: on the road to deliver. Curr Drug Deliv 2005; 2: 253-9.
77. Kohli P, Martin CR. Smart nanotubes for biotechnology. Curr Pharm Biotechnol 2005; 6: 35-47.
78. Donaldson K, Stone V, Tran CL, et al. Nanotoxicology. Occup Environ Med 2004; 61: 727-728.
79. Weissleder R, Papisov M. Pharmaceutical iron oxides for MR imaging. Rev Magn Reson Med 1992; 4: 1-20.
80. Sonvico F, Mornet S, Vasseur S, et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug chem 2005; 16: 1181-8.
81. Leucuta SE. Magnetic microspheres and microcapsules as carriers for intravascular administration of metronidazole. Drug Dev Ind Pharm 1986; 12: 2281-8.
82. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008; 60: 1241-51.
83. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physico-chemical characteristics and clinic al applications. J Drug Target 1998; 6: 167-74.
84. Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomed 2008; 3: 311-21.
85. Baptista P, Pereira E, Eaton P, et al. Gold nanoparticles for the development of clinical diagnosis methods. Anal Bioanal Chem 2008; 391: 943-50.
86. Horisberger M. Colloidal gold: a cytochemical marker for light and fluorescent microscopy and for TEM and scanning electron microscopy. Scan Electron Microsc 1981; 11: 9-31.
87. Liz-Marzán LM. Tailoring surface plasmon resonance through the morphology and assembly of metal nanoparticles. Langmuir 2006; 22: 23-32.
88. Sonvico F, Dubernet C, Colombo P, Couvreur P. Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des 2005; 11: 2091-105.
89. Murakami T, Tsuchida K. Recent advances in inorganic nanoparticle-based drug delivery systems. Mini-Rev Med Chem 2008; 8: 175-83.
90. Duncan R, Ringsdorf H, Satchi Fainaro R. Polymer therapeuticspolymers as drugs, conjugates and gene delivery systems: past, present and future opportunities. Adv Polym Sci 2006; 192: 1-8.
91. Gaspar R, Duncan R. Polymer carriers: preclinical safety and regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 2009; 61: 1220-31.
92. Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J 2006; 8: E466-E478.
93. De Stefano N, Filippi M, Confavreux C, et al. The results of two multicenter open label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymer mixture in patients with relapsing -remitting multiple sclerosis. Mult Scler 2009; 15: 238-43.
94. Dhal PK, Polomoscanik SC, Avila LZ, Holmes-Farley SR, Miller RJ. Functional polymers as therapeutic agents: concept to market place. Adv Drug Deliv Rev 2009; 61: 1211-30.
95. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60
96. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007; 65: 259-69.
97. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60.
98. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-blockpoly(L amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002; 54: 169-90.
99. Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007; 96: 2547-65.
100. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88.
101. Kwon GS, Kataoka K. Block copolymer micelles as longcirculating drug vehicles. Adv Drug Deliv Rev 1995; 16: 295-309
102. Mainardes RM, Silva LP. Drug delivery systems: past, present and future. Curr Drug Targets 2004; 5: 449-55.
103. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethyleneglycol)-lipid conjugate and positively charged lipids. J Drug Target 2005; 13: 73-80.
104. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911 a micelle encapsulated doxorubicin. Br J Cancer 2004; 91: 1775-81.
105. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH. In vivo evaluation of polymeric micellar paclitaxel formulation, toxicity and efficacy. J Control Release 2001; 72: 191-202.
106. Watanabe M, Kawano K, Yokoyamab M, Opanasopit P, Okanoc TYM. Preparation of camptotecin loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 2006; 308: 183-9.
107. Batrakova EV, Li S, Li Y, Alakhov VY Elmquist WF, Kabanov AV. Distribution kinetics of a micelle forming block copolymer Pluronic P85. J Control Release 2004; 100: 389-97.
108. Chang TMS. Artificial cells as bioreactive biomaterials. J Biomater Appl 1988; 3: 116-25.
109. Chang TMS. Therapeutic applications of polymeric artificial cells. Nat Rev 2005; 4: 221-35.
110. Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev 2009; 61: 1131-48.
111. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688-701.
112. Vicent MJ. Polymer-drug conjugates as modulators of cellular apoptosis. AAPS J 2007; 9: E200-E207
113. Segal E, Satchi-Fainaro R. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 2009; 61: 1159-76.
114. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009; 61: 1177-88.
115. Svenson S, Tomalia DA. Dendrimers in biomedical applicationsreflections on the field. Adv Drug Deliv Rev 2005; 57: 2106-29.
116. Al-Jamal KT, Ramaswamy C, Florence AT. Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev 2005; 57: 2238-70.
117. Yang H, Kao WJ. Dendrimers for pharmaceutical and biomedical applicatios. J Biomater Sci Polym Ed 2006; 17: 3-19.
118. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001; 6: 427-36.
119. Merino S, Brauge L, Caminade AM, Majoral JP, Taton D, Gnanou Y. Synthesis and characterization of linear, hyperbranched, and dendrimer like polymers constituted of the same repeating unit. Chemistry 2001; 7: 3095-105.
120. Hecht S, Frechet JMJ. Dendritic encapsulation of function: applying naturès site isolation principle from biomimetics to material science. Angew Chem Int Ed Engl 2001; 40: 74-91.
121. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 2000; 11: 910-17.
122. Caminade AM, Laurent R, Majoral JP. Characterization of dendrimers. Adv Drug Deliv Rev 2005; 57: 2130-46.
123. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005; 57: 2177-202.
124. Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JMJ, Szoka FC Jr. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluations. Bioconjug Chem 2002; 13: 453-61.
125. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracyl. Int J Pharm 2003; 257: 111-24.
126. Kono K, Liu M, Frechet JKMJ. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjug Chem 1999; 10: 1115-21.
127. Lundquist JJ, Toone EJ. The cluster glycoside effect. Chem Rev 2002; 102: 555-78.
128. Benito JM, Gomez-Garcia M, Mellet CO, et al. Optimizing saccharide directed molecular delivery to biological receptors: design, synthesis and biological evaluation of glycodendrimercyclodextrin conjugates. J Am Chem Soc 2004; 126: 10355-63.
129. Boas U, Heegaard PMH. Dendrimers in drug research. Chem Soc Rev 2004; 33: 43-63.
130. Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C. Synthesis and biological studies of 5-aminolevulinic acid containing dendrimers for photodynamic therapy. Bioconjug Chem 2001; 12: 980-8.
131. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower generation polypropyleneimine dendrimers are effective gene transfer agents. Pharm Res 2002; 19: 960-7.
132. Eichman JD, Bielinska AU, et al. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technol Today 2000; 3: 232-45.
133. Vinogradov SV. Colloidal microgels in drug delivery applications. Curr Pharm Des 2006; 12: 4703-12.
134. Caldorera Moore M, Peppas NA. Micro and nanotechnologies for intelligent and responsive biomaterial-based medical systems. Adv Drug Deliv Rev 2009; 61: 1391-401.
135. Hilt JZ, Byrne ME. Configurational biomimesis in drug delivery: molecular imprinting of biologically significant molecules. Adv Drug Deliv Rev 2004; 56: 1599-620.
136. Cimalla V, Niebelschütz F, Tonisch K, et al. Nanoelectromechanical devices for sensing applications, Functional Materials for Micro and Nanosystems -EMRS, Sens Actuators B. Chem 2007; 126: 24-34.
137. LaHaye MD, Buu O, Camarota B, Schwab KC. Approaching the quantum limit of a nanomechanical resonator. Science 2004; 304: 74-7.
138. Peng HB, Chang CW, S Aloni, Yuzvinsky TD, Zettl A. Microwave electromechanical resonator consisting of clamped carbon nanotubes in an abacus arrangement. Phys Rev B 2007; 76(3). id. 035405
139. Fennimore AM, Yuzvinsky TD, Han W-Q, Fuhrer MS, Cumings J, Zettl A. Rotational actuators based on carbon nanotubes. Nature 2003; 424: 408-10.
140. Li M, Tang HX, Roukes ML. Ultra-sensitive NEMS-based cantilevers for sensing, scanned probe and very high-frequency applications. Nat Nanotechnol 2006; 2: 114-20.
141. Tsuchiya Y, Takai K, Momo N, Nagami T, Mizuta H, Oda S. Nanoelectromechanical nonvolatile memory device incorporating nanocrystalline Si dots. J Appl Phys 2006; 100: 094306
142. Besteman K, Lee JO, Wiertz FGM, Heering HA and Dekker C. Enzyme-coated carbon nanotubes as single-molecule biosensors. Nano Lett 2003; 3: 727-30.
143. Cui Y, Wei Q, Park H, Lieber CM. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 2001; 293: 1289-92.
144. Postma HWCh., Teepen T, Yao Z, Grifoni M, Dekker C. Carbon nanotube single-electron transistors at room temperature, Science 2001; 293(5527): 76-9.
145. Kinaret JM, Nord T, Viefers S A. Carbon-nanotube-based nanorelay. Appl Phys Lett 2003; 82: 1287-9.
146. Kaul AB, Wong EW, Epp L, Hunt BD. Electromechanical carbon nanotube switches for high-frequency applications. Nano Lett. 2006; 6: 942-7.
147. Chen Y, Wang X, Erramilli S, Mohantya P, Kalinowski A. Siliconbased nanoelectronic field-effect pH sensor with local gate control. Appl Phys Lett 2006; 89: 223-512.
148. Lee YS, Mrksich M. Protein chips: from concept to practice. Trends Biotechnol 2002; 20: S14-S18.
149. Manz A, Gaber N, Widmer J. Miniaturized total chemical analysis system: a novel concept for chemical sensing. Sens Actuators B 1990; 1: 244-8.
150. Kubik T, Bogunia-Kubik K, Sugisaka M. Nanotechnology on duty in medical applications. Curr Pharm Biotechnol 2005; 6: 17-33.
151. Turner APF, Karube I, Wilson GS. Biosensors: fundamentals and applications. Oxford University Press, 1987.
152. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev 2005; 5: 161-71.
153. Fritz J, Baller MK, Lang HP, et al. Translating biomolecular recognition into nanomechanics. Science 2000; 288: 316-8.
154. Ilic B, Yang Y, Aubin K, et al. Enumeration of DNA molecules bound to a nanomechanical oscillator. Nano Lett 2005; 5: 925-9.
155. Joshi PP, Merchant SA, Wang Y, Schmidtke DW. Amperometric biosensors based on redox polymer-carbon nanotubes-enzyme composites. Anal Chem 2005; 7: 3183-8.
156. Barone PW, Baik S, Heller DA, Strano MS. Near-infrared optical sensors based on single walled carbon nanotubes. Nat Mater 2004; 4: 86-92.
157. Patolsky F, Zheng G, Hayden O, et al. Electrical detection of single viruses. Proc Natl Acad Sci USA 2004; 101: 14017-22.
158. Shi D. Integrated multifunctional nanosystems for medical diagnosis and treatment. Adv Funct Mater 2009; 19: 3356-73.
159. Van Vlerken LE, Amiji MM. Multi functional polymeric nanoparticles for tumor targeted drug delivery. Expert Opin Drug Deliv 2006; 3: 205-16.
160. Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomed Nanotechnol Biol Med 2007; 3: 103-10.
161. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006; 58: 1532-55.
162. Jain KK. Role of nanobiotechnology in the development of personalized medicine. Nanomedicine 2009; 4: 249-52.
163. Park JH, Gvon M, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed 2008; 47: 7284-8.
164. Macdonald F, Ford C H J. The Molecular Biology of Cancer. Bios Scientific Publishers, 1997.
165. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. Lippincott Williams & Wilkins, 2001.
166. Kinzle Sherr, C J. Cell cycle control and cancer. Harvey Lect 2000; 96: 73.
167. Friedberg E. DNA damage and repair. Nature 2003; 421: 436-40.
168. Hunter T. Cooperation between oncogenes. Cell 1991; 64: 249-70.
169. Weinberg RA. Tumor supressor genes. Science 1991; 254: 1138-46.
170. Weinberg RA. Tumor supressor genes. Science 1991; 254: 1138-46.
171. Pathak P, Katiyar VK, Giri S. Cancer resarch -nanoparticles, nanobiosensors and their use in cancer research. J Nanotechnol online 12 Sept. 2007, DOI. 10.2240/azojono0116
172. Brannon Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649-59.
173. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging and senssing. Anal Bioanal Chem 2006; 384: 620-30.
174. Hartman KB, Wilson LJ, Rosenblum MG. Detecting and treating cancer with nanotechnology. Mol Diag Ther 2008; 12: 1-14.
175. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev 2005; 5: 161-71.
176. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9: E128-E147.
177. Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul 2007; 1: 37-51.
178. Budihardjo I, Oliver H. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Biol 1999; 15: 269-90
179. Serpe L. Conventional chemotherapeutic drug nanoparticles for cancer treatment. In: Challa SSR Kumar Ed. Nanomaterials for cancer therapy. Wiley-VCH Verlag GmbH &Co., Weinheim, 2006; Chap. 1: pp. 1-39.
180. Iverson N, Plourde N, Chnari E, Nackman GB, Moghe PV. Convergence of nanotechnology and cardiovascular medicine. Biodrugs 2008; 2: 1-10.
181. Brito L, Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomed 2007; 2: 143-61.
182. Patel DN, Bailey SR. Nanotechnology in cardiovascular medicine. Catheter Cardiovasc Interv 2007; 69: 643-54.
183. Shetty RC. Benefits of nanotechnology in cardiovascular surgery- review of potential applications. US Cardiovasc Dis 2006; 1-2.
184. Nawarskas JJ, Osborn LA. Paclitaxel eluting stents in coronary artery disease. Am J Health Syst Pharm 2005; 62: 2241-51.
185. Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002; 106: 599-605.
186. Sharma KK, Sangraula H, Mediratta PK. Some new concepts in antibacterial drug therapy. Ind J Pharmacol 2002; 34: 390-6.
187. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection, 2001; 29 Suppl.2: 11-5.
188. Fielding RM, Lasic DD. Liposomes in the treatment of infectious diseases. Exp Opin Ther Pat 1999; 9: 1679-88.
189. Maesaki S. Drug delivery system of antifungal and parasitic agents. Curr Pharm Des 2002; 8: 433-40.
190. Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomed 2006; 1: 417-32.
191. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006; 7: 65-74.
192. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-12.
193. Smith QR. Advances in neurology. In: Alzheimers disease, Wurtman R. Ed., Raven Press: New York 1990; 51: 217-22.
194. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases Int J Nanomed 2008; 3: 1-19.
195. Sung J C, Pulliam B L, Edwards DA. Nanoparticles for drug delivery to the lungs Trends Biotechnol 2005; 25: 563-570.
196. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery Int J Nanomed 2009; 4: 299-319.
197. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006; 533(1-3): 341-50.
198. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery Respir Med 2003; 97: 382-87.
199. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 2009; 29: 196-212.
200. Colombo P, Cocconi D, Santi P, et al. Biopharmaceutical aspects of nasal and pulmonary drug delivery, In: Testa B, van de Waterbeemd H, Folkers G, Guy R, Eds. Pharmacokinetic Optimization in Drug Research, Verlag Helvetica Chimica Acta, Zürich, 2001; 173-188.
201. Colombo P, Catellani PL, Massimo G, et al. Surface smoothing of lactose particles for dry powders inhalers. Respir Drug Deliv 2000; 629-32.
202. Sham JOH, Zhang Y, Finlay W H, Roa W H, Löbenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004; 269: 457-67.
203. Wolff RK, Niven RW. Generation of aerosolized drugs. J Aerosol Med 1994; 7(1): 89-106.
204. Larhrib H, Martin GP, Marriott C, Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 2003; 257(1-2): 283-96.
205. Edmonds ML, Camargo CA, Jr., Brenner BE, Rowe BH. Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: a meta-analysis. Chest 2002; 121(6): 1798-1805.
206. Beck-Broichsitter M, Gauss J, Gessler T, Seeger W, Kissel T, Schmehl T. Pulmonary targeting with biodegradable salbutamolloaded nanoparticles. J Aerosol Med Pulm Drug Deliv 2010; 23(1): 47-57.
207. Bhavna, Ahmad FJ, Mittal G, Jain GK, Malhotra G, Khar RK, Bhatnagar A. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 2009; 71(2): 282-91.
208. Kompella UB, Bandi N, Ayalasomayajula SP. Poly (lactic acid) nanoparticles for sustained release of budesonide. Drug Deliv Technol 2001; 1(1): 1-3.
209. Tam Jm, Mcconville Jt, Williams Iii Ro, Johnston KP. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 2008; 97: 4915-33.
210. Jie Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008; 356 (1-2): 333-44.
211. Klinger C, Müller BW, Steckel H. Insulin micro-and nanoparticles for pulmonary delivery. Int J Pharm 2009; 377(1-2): 173-9.
212. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981-6.
213. Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009; 26: 1847-55.
214. Skiba M, Bounoure F, Barbot C, Arnaud P, Skiba M. Development of cyclodextrin microspheres for pulmonary drug delivery. J Pharm Pharm Sci 2005: 8: 409-18.
215. Hennin PA, Hein S, Schneider M, Bur M, Lehr CM. Pulmonary Drug Delivery: Medicines for Inhalation, Springer Berlin Heidelberg, 2009.
216. Patton, J.S., Platz, R.M. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8:179-96.
217. Courrier, H.M., Butz, N., Vandamme, T.F. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002; 19: 425-98.
218. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59: 478-90.
219. Bennett JV, de Caastro JF, Valdespino-Gomez JL, et al. Aerosolized measles and measles rubella vaccines induce better measles antibody booster response than injected vaccine: randomized trials in Mexican school children. Bull World Health Organ 2002; 80: 806-12.
220. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 2008; 295: L400-L411.
221. Ana Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005; 25: 427-37.
222. Mastrobbattista E, van der Aa MAEM, Hennink WE, Crommelin DJA Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 2006; 5: 115-21.
223. Kayser O, Kiderlen AF. Nonviral gene transfer systems in somatic gene therapy. In: Kayser O, Muller RH, Eds. Pharmaceutical Biotechnology, Drug Discovery and Clinical Applications. Wiley-VCH Verlag GmbH & Co.: Weinheim 2004; pp. 249-63.
224. Schweitzer M, Flory E. Somatic Gene Therapy -Advanced Biotechnology Products in Clinical Development. In: Kayser O, Muller RH, Eds. Pharmaceutical Biotechnology, Drug Discovery and Clinical Applications. Wiley-VCH Verlag GmbH & Co.: Weinheim 2004.
225. Fattal E Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm 2008; 364: 237-48.
226. Glover DJ, Lipps HJ, Jans DA. Towards safe, nonviral therapeutic gene expression in humans. Nat Rev Genet 2005; 6: 299-310.
227. Al-Dosari M, Gao X. Nonviral gene delivery: principle, limitations and recent progress. AAPS J 2009; 11: 671-80.
228. Gao X, Sik-Kim K, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J 2007; 9: E92-E103.
229. Parker A L, Newman C, Briggs S, Seymour L, Sheridan PJ. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Rev Mol Med 2003; 5: 1-15.
230. Branden, L J, Christensson B, Smith, C I. Methods Enzymol. In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. Gene Ther 2001; 8: 84-7.
231. Simonson OE, Svahn MG, Tornquist E, Lundin KE, Smith CI. Bioplex technology: novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids. Curr Pharm Des 2005; 11: 3671-80.
232. Oprea II, Simonson OE, Moreno PM, Viola JR, Lundin KE, Smith CIE. Temperature-assisted cyclic hybridization (TACH): an improved method for hybridization. Mol Biotechnol 2010; 45: 171-9.
233. Langer R, Vacanti JP. Tissue engineering. Science 1993; 260: 920-6.
234. Venugopal J, Low S, Choon AW, Ramakrishna S. Interaction of cells and nanofiber scaffolds. J Biomed Mater Res 2008; 84: 34-48.
235. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Edn 2007; 18: 241-68.
236. Smith LA, Ma PX. Nanofibrous scaffolds for tissue engineering. Colloids Surf B Biointerfaces 2004; 39: 125-31.
237. Hasirci V, Vranba E, Zorlutuna P, et al. Nanobiomaterials: a review of the existing science and technology and new approaches. J Biomater Sci Polym Edn 2006; 17: 1241-68.
238. Venugopal J, Ramakrishna S. Biocompatible nanofiber matrices for the engineering of a dermal substitute for skin regeneration. Tissue Eng 2005; 1: 1452-4.
239. Kim K, Fisher JP. Nanoparticle technology in bone tissue engineering. J Drug Target 2007; 15: 241-52.
240. Khademhosseini A, Langer R. Nanobiotechnology. Drug delivery and tissue engineering. Nanobiotechnology SBE special section, 2005; 38-42.
241. Li SD, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol Pharm 2008; 5: 496-504.
242. Owens D E, Peppas N A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
243. Leucuta S E, Achim M, Risca R, Postescu I D: Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. STP Pharm Sci 2003; 13: 291-7.
244. Balacescu O, Kauffmann A, Vlase L, Neagoe I, Leucuta SE. Improved pharmacokinetics and modified pharmacogenomics of doxorubicin loaded liposomes vs. free drug administered in mice. 33rd Annual Meeting of the Controlled Release Society. Vienna 22-26 July 2006 p. 349.
245. Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJA. Nanotoxicology. Occup Environ Med 2004; 61: 727-8.
246. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113: 823-39.
247. European Commission. Nanotechnologies: a preliminary risk analysis on the basis of a workshop organized in Brussels on 1-2 March by the Health and Consumer Protection Directorate General of the European Commission. 2004. Available from: http: //europa. eu.int/comm/health/ph_risk/documents/ev_20040301_en.pdf
248. Donaldson K, Stone V, et al. Ultrafine particles: mechanisms of lung injury. Trans R Soc Lond A 2000; 358: 2741-9.
249. De Jong WH, Roszek B, Geertsma RE. Nanotechnology in medical applications: possible risks for human health. RIVM Report 265001002/2005, 1-46.
250. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles, potential implications for drug delivery. J Nanosci Nanotechnol 2004; 4: 521-31.